Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 29.80
Change Today -0.10 / -0.33%
Volume 278.9K
MDGS On Other Exchanges
Symbol
Exchange
OTC US
NASDAQ CM
Tel Aviv
As of 10:24 AM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

medigus ltd (MDGS) Snapshot

Open
$29.90
Previous Close
$29.90
Day High
$30.10
Day Low
$29.20
52 Week High
04/14/15 - $58.90
52 Week Low
12/30/14 - $25.00
Market Cap
95.5M
Average Volume 10 Days
707.3K
EPS TTM
$-0.11
Shares Outstanding
320.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDIGUS LTD (MDGS)

Related News

No related news articles were found.

medigus ltd (MDGS) Related Businessweek News

No Related Businessweek News Found

medigus ltd (MDGS) Details

Medigus Ltd., a medical device company, designs, develops, and sells minimally invasive endosurgical tools and imaging solutions. It offers the MUSE system, a proprietary disposable endoscopic device comprising a micro-camera, a surgical endostapler, and an ultrasound sensor for the treatment of gastroesophageal reflux disease. The company was founded in 1999 and is headquartered in Omer, Israel.

Founded in 1999

medigus ltd (MDGS) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: 1.3M
Founder
Total Annual Compensation: --
Vice President, Omer
Total Annual Compensation: 517.0K
Executive Vice President
Total Annual Compensation: 523.0K
Director of Finance & Accounting and Vice Pre...
Total Annual Compensation: 503.0K
Compensation as of Fiscal Year 2014.

medigus ltd (MDGS) Key Developments

MediGus Ltd.(NasdaqCM:MDGS) added to NASDAQ Composite Index

MediGus Ltd. has been added to Nasdaq Composite Index.

Medigus Ltd. Announces Executive Changes

Medigus Ltd. announced the appointment of new senior executives and several U.S. regional sales managers. Doron Birger was appointed to the Board of Directors and Jeremy Starkweather was appointed as the new Vice President of U.S. Sales and Marketing. On August 1, 2015 Gilad Mamlok commenced his engagement as Chief Financial Officer. Doron Birger currently serves as a director of three publicly-traded life sciences companies in Israel (Hadasit Bio-Holdings Ltd., IceCure, and Medical Compression Systems), and as chairman and director of several private companies in the high-technology medical device space. He previously served as director and chairman of the board of Given Imaging, and as Chief Executive Officer of Elron Electronic Industries Ltd., from 2002 until 2009. For all of these innovative, Israeli-based, medical device companies, he has played in a pivotal role in aligning their strategic direction, clinical and commercial planning. Gilad Mamlok brings over two decades of financial management and business development experience to his new role at Medigus. He previously was at the helm of corporate financial planning, including leading mergers and acquisitions, investor relations and corporate governance, for several public and private medical device and technology companies located in Israel and the U.S. Most recently, he served as Vice President of Finance at Covidien plc, following its acquisition of Given Imaging, where he was Senior Vice President, Global Finance and Accounting since 2005.

Medigus Ltd. Receives Approval from Israeli Ministry of Health to Market the Muse(TM) System

Medigus Ltd. announced that the company has received approval from the Israeli Ministry of Health (MOH) to market the Medigus Ultrasonic Surgical Endostapler, or MUSE™ system in Israel. The new MOH approval takes effect immediately and will expire in December 2016. The MUSE system is also FDA cleared and CE marked for the treatment of GERD in the United States and Europe, respectively. The new approval of the MOH was granted to Medigus following the expiration in February 2014 of the previously granted approval.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDGS:IT 29.80 -0.10

MDGS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MDGS.
View Industry Companies
 

Industry Analysis

MDGS

Industry Average

Valuation MDGS Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDIGUS LTD, please visit www.medigus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.